MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Epithelioid

Epitheliod mesothelioma makes up between 50% and 70% of all diagnosed cases of mesothelioma; it also tends to have the best prognosis.

BAP1 Loss is a Useful Adjunct to Distinguish Malignant Mesothelioma Including the Adenomatoid-like Variant From Benign Adenomatoid Tumors.

Applied Immunohistochemistry & Molecular Morphology 2019 January 11 [Link] Erber R, Warth A, Muley T, Hartmann A, Herpel E, Agaimy A Abstract Malignant mesothelioma (MM) can show areas closely mimicking reactive mesothelial proliferations or recapitulating benign adenomatoid tumors (ATs) making distinction on occasion impossible on morphologic ground alone, particularly in limited biopsy material. Recently, loss […]

Comments Off on BAP1 Loss is a Useful Adjunct to Distinguish Malignant Mesothelioma Including the Adenomatoid-like Variant From Benign Adenomatoid Tumors.

Factors influencing malignant mesothelioma survival: a retrospective review of the National Mesothelioma Virtual Bank cohort.

F1000Research 2018 August 3 [Link] Amin W, Linkov F, Landsittel DP, Silverstein JC, Becich MJ Abstract Background: Malignant mesothelioma (MM) is a rare but deadly malignancy with about 3,000 new cases being diagnosed each year in the US. Very few studies have been performed to analyze factors associated with mesothelioma survival, especially for peritoneal presentation. […]

Comments Off on Factors influencing malignant mesothelioma survival: a retrospective review of the National Mesothelioma Virtual Bank cohort.

Malignant mesothelioma: A histomorphological and immunohistochemical study of 24 cases from a tertiary care hospital in Southern India.

Indian Journal of Cancer 2018 April-June [Link] Hui M, Uppin SG, Bhaskar K, Kumar NN, Paramjyothi GK Abstract BACKGROUND: Malignant mesotheliomas are histologically heterogeneous neoplasms. Definite diagnosis requires a varied panel of immunohistochemical (IHC) markers to differentiate these from histological mimics. Only a few case series have been reported in the Indian literature where mesotheliomas […]

Comments Off on Malignant mesothelioma: A histomorphological and immunohistochemical study of 24 cases from a tertiary care hospital in Southern India.

Complex Immune Contextures Characterise Malignant Peritoneal Mesothelioma: Loss of Adaptive Immunological Signature in the More Aggressive Histological Types.

Journal of Immunology Research 2018 October 29 [Link] Tazzari M, Brich S, Tuccitto A, Bozzi F, Beretta V, Spagnuolo RD, Negri T, Stacchiotti S, Deraco M, Baratti D, Camisaschi C, Villa A, Vergani B, Rivoltini L, Pilotti S, Castelli C Abstract Malignant peritoneal mesothelioma (MpM), arising in the setting of local inflammation, is a rare […]

Comments Off on Complex Immune Contextures Characterise Malignant Peritoneal Mesothelioma: Loss of Adaptive Immunological Signature in the More Aggressive Histological Types.

Primary Malignant Deciduoid Mesothelioma: A Challenging Diagnosis.

Archives of Pathology & Laboratory Medicine 2018 November 30 [Link] Regragui M, Guebessi NB Abstract Primary malignant deciduoid mesothelioma is a rare subtype of epithelioid mesothelioma that was first described in the peritoneum in young women without a history of asbestos exposure. It was thought to be a distinct clinicopathologic entity with ominous prognosis; recent […]

Comments Off on Primary Malignant Deciduoid Mesothelioma: A Challenging Diagnosis.

Treatment of malignant pleural mesothelioma with chemotherapy preceding versus after surgical resection.

The Journal of Thoracic and Cardiovascular Surgery 2018 October 22 [] Verma V, Ahern CA, Berlind CG, Lindsay WD, Grover S, Friedberg JS, Simone CB Abstract OBJECTIVES: There are 2 main treatment paradigms recognized by the National Comprehensive Cancer Network for resectable malignant pleural mesothelioma (MPM): induction chemotherapy followed by resection (IC/R), and up-front resection […]

Comments Off on Treatment of malignant pleural mesothelioma with chemotherapy preceding versus after surgical resection.

Real-life treatment practice for malignant pleural mesothelioma in Belgium.

Lung Cancer 2018 November [Link] Rosskamp M, Macq G, Nackaerts K, Praet M, Van Eycken L, Van Meerbeeck JP, De Schutter H Abstract OBJECTIVES: Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer, for which treatment is often limited to palliative combination chemotherapy. Multimodality-therapy, including radical surgery, is largely restricted to clinical trials, leaving […]

Comments Off on Real-life treatment practice for malignant pleural mesothelioma in Belgium.

Well-differentiated papillary mesothelioma: A 17-year single institution experience with a series of 75 cases.

Annals of Diagnostic Pathology 2018 October 28 [Link] Sun M, Zhao L, Weng Lao I, Yu L, Wang J Abstract We present our experience with 75 cases of well-differentiated papillary mesothelioma (WDPM) that were diagnosed at our institution between 2000 and 2017. The patients included 58 females and 17 males with age ranging from 18 […]

Comments Off on Well-differentiated papillary mesothelioma: A 17-year single institution experience with a series of 75 cases.

Malignant mesothelioma of tunica vaginalis testis: Report of a very rare case with review of the literature.

Archivio Italiano di Urologia, Andrologia 2018 September 30 [Link] Trenti E1, Palermo SM, D’Elia C, Comploj E, Pycha A, Carella R, Pycha A Abstract INTRODUCTION: Mesothelioma of the tunica vaginalis testis is a extremely rare tumor and represents 0.3 to 0.5% of all malignant mesotheliomas. Exposure to asbestos often precedes illness. Because of its low […]

Comments Off on Malignant mesothelioma of tunica vaginalis testis: Report of a very rare case with review of the literature.

MUC21 is a novel, negative immunohistochemical marker for epithelioid mesothelioma for its differentiation from lung adenocarcinoma.

Histopathology 2018 October 17 [Link] Kai Y1,2, Amatya VJ1, Kushitani K, Kambara T, Suzuki R, Tsutani Y, Miyata Y, Okada M, Takeshima Y Abstract AIMS: The process of differential diagnosis between epithelioid mesothelioma and lung adenocarcinoma has been progressing; however, there are no absolute immunohistochemical markers to definitively diagnose epithelioid mesothelioma. The aim of this […]

Comments Off on MUC21 is a novel, negative immunohistochemical marker for epithelioid mesothelioma for its differentiation from lung adenocarcinoma.